....and management may want to address this Duzi Advanced...

First 102 Last

Share
Profile

Follow
aburbe

1,096 Posts.

267

18/10/18

06:18

Post #: 36165601
Share

Originally posted by NZ Trader ↑

You are correct in the first instance about compromising the study.
The DSMB / Medsafe monitor the Trial Patients through out the trial, they are not privy to the Placebo Patients identity.
Not only do they monitor for negative effects and side effects ,,the trial as it progresses has to show " Significant Positive Benefit to the Trial Patients" so to answer many questions at once, To Date there has been no negative side effects and we know Medsafe will only be satisfied with Significant Positive Benefits , ergo that must have been achieved to date.
ACW had interim Data as many Trial Patients had completed the entire trial including a monitoring period , we know that stimulated a $15m investment at a premium to the SP. (for me it took considerable risk off the table)
PAA has an exit with Elanco on Monepantal.
When BOT narrow down and disclose the party or parties that are probable buyers or licensees of the Technology and the magnitude of the commercial outcome is understood by the wider market you will see BOT shares under such incredible demand and as always at that point,,,,,wishing you had more...
In rocky times the market avoids uncertainty ..... BOT Management may want to address that and provide more information on the commercial opportunity for investing in BOT??

Expand

....and management may want to address this Duzi Advanced Cosmetic Laser Clinic mob from South Africa....(WTF?)

https://www.news24.com/SouthAfrica/Local/Maritzburg-Fever/curiousity-over-cannabidiol-20181016

http://www.imgoor.com/instagram-hashtag/globalderm/

BOT Price at posting: 8.7¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

Ice-cold winner: Cryopreserver Vitrafy escapes November's IPO struggles to end debut week higher

HotCopper Highlights: Your most watched stocks for Week 48, 2024

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Week 48 Wrap: ASX flirts with 8,500pts; APRA declines mortgage loan easing; Trump's Bessent tied to Dem donor

ACW

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Dale Gillham's weekly wrap: Bold moves in NZ, caution in Australia

ADD

Parkes Au-Cu project to 'transform' Adavale Resources with key targets

RSG

Resolute shares bounce back as second payment made to Mali government to secure workers' release

There are more pages in this discussion • 10 more messages in this thread...

First 102 Last

Add BOT (ASX) to my watchlist

(20min delay)
Last 36.0¢		Change -0.005(1.37%)		Mkt cap ! $707.4M

Open	High	Low	Value	Volume
36.5¢	37.0¢	36.0¢	$391.8K	1.080M

Buyers (Bids)

No.	Vol.	Price($)
3	160000	35.5¢

Sellers (Offers)

Price($)	Vol.	No.
36.0¢	11013	2

View Market Depth

No.	Vol.	Price($)
11	423267	0.105
23	1189777	0.100
1	10111	0.099
1	50000	0.098
1	50000	0.097

Price($)	Vol.	No.
0.110	555657	10
0.115	560304	6
0.120	829451	14
0.125	1083838	12
0.130	498290	12

Last trade - 16.10pm 29/11/2024 (20 minute delay)

BOT (ASX) Chart

....and management may want to address this Duzi Advanced...

Top Stories

Ice-cold winner: Cryopreserver Vitrafy escapes November's IPO struggles to end debut week higher

HotCopper Highlights: Your most watched stocks for Week 48, 2024

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Week 48 Wrap: ASX flirts with 8,500pts; APRA declines mortgage loan easing; Trump's Bessent tied to Dem donor

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Dale Gillham's weekly wrap: Bold moves in NZ, caution in Australia

Parkes Au-Cu project to 'transform' Adavale Resources with key targets

Resolute shares bounce back as second payment made to Mali government to secure workers' release

Buyers (Bids)

Sellers (Offers)